课题基金 / 基金详情

CAF VS CAF AND ADR-529 IN THE TREATMENT OF DISSEMINATED BREAST CANCER

CAF VS CAF AND ADR-529 IN THE TREATMENT OF DISSEMINATED BREAST CANCER
CAF 与 CAF 和 ADR-529 治疗播散性乳腺癌的比较
批准号：
3763663
负责人：
JAMES SPEYER
金额：
$0.0万
依托单位：
NEW YORK UNIVERSITY
依托单位国家：
美国
项目类别：
财政年份：
--
资助国家：
美国
项目状态：
未结题
起止时间：
至
来源：
https://reporter.nih.gov/project-details/3763663
关键词：
antineoplastics breast neoplasms cardiovascular disorder prevention clinical trials combination chemotherapy cyclophosphamide doxorubicin drug interactions drug screening /evaluation human subject human therapy evaluation intravenous administration neoplasm /cancer chemotherapy vincristine

项目摘要

项目成果

JAMES SPEYER的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
The objectives of this trial are to demonstrate that ADR-529, administered intravenously, has a cardioprotective effect when added to the CAF regimen in patients with disseminated carcinoma of the breast. Also, it will determine if ADR-529 alters response rate between the two arms of the study. Finally, this study will assess the safety of the combination of CAF with ADR-529.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Protocol Review and Monitoring
WEEKLY ONE HOUR PACLITAXEL IN REFRACTORY METASTATIC BREAST CANCER
WEEKLY ONE HOUR PACLITAXEL IN REFRACTORY METASTATIC BREAST CANCER
DEXRAZOXANE, DOXORUBICIN & ESCALATING DOSES OF PACLITAXEL IN ADVANCED BREAST CA
海外基金